After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm

What will the next life sciences unicorn be? If you ask venture capitalist Chris Velis’ son, it could come from his new Cambridge investment firm.

“Dad, I get it. You don’t search for unicorns. You breed them,” Velis recalled one of his sons saying during a recent meeting at the Harvard Square headquarters of his new medtech-focused venture creation firm, Miraki Innovation.